Can I advertise GLP-1 medication on Meta?

Yes, but prescription-drug advertising is subject to Meta's authorization and eligibility requirements. For GLP-1 advertisers, eligibility can depend on the product, advertiser type, market, and authorization status. In our monitored accounts, we also see the ad, landing page, and business information need to remain consistent with the product being advertised.

Why do my GLP-1 ads keep getting rejected even when the products are legitimate?

GLP-1 advertising operates in a restricted and closely scrutinized policy area, so authorization, product positioning, creative, landing-page content, and other account signals can all affect enforcement. In our monitored accounts, we see some rejections on ads that appear compliant on manual review. Our recovery analysis shows that appeals referencing the specific enforcement signal can perform differently from generic appeals.

What is the appeal success rate for GLP-1 enforcement decisions?

In our Q2 2026 Intelligence Graph, 30-35% of GLP-1 appeals that referenced the exact violation code resulted in an overturn. Generic appeals performed materially worse in our observed cohort.

Can I use brand-name drug references (Wegovy, Ozempic) in my ads?

Brand-name references such as Wegovy or Ozempic can introduce additional compliance considerations, particularly when the advertiser is promoting a different product such as a compounded medication. In our monitored cases, brand references have been associated with authority mismatches and additional review. Make sure the product described in the ad and landing page matches the product and authorization held by the advertiser.

What is categorical enforcement?

Categorical enforcement is the term we use to describe a pattern we observe in highly restricted advertising verticals. In these lanes, the category itself creates additional compliance constraints before individual creative decisions are considered. For GLP-1 advertisers, authorization and product eligibility can be gating factors alongside creative and landing-page compliance.

Meta Ad Compliance for Weight Loss & GLP-1

Q: My GLP-1 telehealth account was disabled with a policy-code disablement. Can I get it back?

Likely not by direct appeal. A May 2026 Meta Pro Team response reviewed by ComplyAi indicated that policy-code disablements in this GLP-1 telehealth case were typically non-appealable. That does not guarantee the same outcome for every account. When this happens, our recovery approach shifts from the disabled account to protecting other connected accounts and business assets from potential enforcement exposure.

SECTION 01 · Categorical enforcement

Why this vertical sits at Meta's highest enforcement tier

GLP-1 telehealth authorization flow: LegitScript certification then Meta authorization

If you run GLP-1 or weight-loss telehealth ads on Meta, you are in Meta's toughest lane. Meta classifies prescription-drug advertising within its restricted Drugs and Pharmaceuticals framework. This is the enforcement pattern we call categorical enforcement. In our observed enforcement pattern, authorization status can become the gating issue before creative-level compliance determines the outcome.

What this means in practice:

Compliant ads can still be rejected. Ads that follow the rules can still be rejected. In our monitored accounts, we have observed compliant ads receive enforcement, which is why the appeal pipeline matters.
Account disablement moves fast. Repeat policy rejections on one ad account can drive disablement. The window is short. Bans can land within weeks (subscriber observation, exact window varies).
Business identity is your real currency. Our monitoring shows enforcement can extend across connected business assets, identities, and payment relationships.
Compounded GLP-1 is enforced separately from FDA-approved GLP-1. Meta treats them as different products. For compounded products, our monitored cases show that clear regulatory disclosures and licensed-provider documentation are important compliance signals.

Across the accounts we track, GLP-1 telehealth enforcement has shown faster cascade patterns than supplements and lower-risk lanes. This pattern is based on our ComplyAi Intelligence Graph, Q2 2026. The Enforcement Behavior signature here sits at the category level, not the creative level. Compliance work has to fix the lane's risk model, not just one ad.

The authorization gate that stops most GLP-1 ads before enforcement even fires

Most GLP-1 telehealth failures in our data are not creative rejections. They are account-never-authorized failures. The advertiser launched GLP-1 ads without third-party certification. In our monitored cases, unauthorized accounts have seen repeated rejection regardless of how compliant the creative appeared.

Meta's Prescription Drugs policy sets this gate (Business Help Center: "About Meta's Prescription Drugs advertising policy"). Prescription-drug ads need prior Meta authorization. Only three entity types qualify: drug makers, online pharmacies, and telehealth providers.

For GLP-1 telehealth, the path looks like this:

Certify with LegitScript. LegitScript is the third-party verifier Meta uses for prescription-drug eligibility. Certification is per country. No active LegitScript, no Meta application.
Submit for Meta authorization. Apply through the Authorizations and verifications tab in Meta Business Suite. Give the LegitScript-certified URL, business name, and the ad accounts.
Maintain LegitScript. If it lapses, Meta pulls the authorization.

Drug makers have a second path: Meta's internal review. It needs FDA registration (or the local equal). It skips LegitScript. Telehealth does not get that option. LegitScript is the only route for telehealth.

Country scope is narrow. Meta allows prescription-drug ads in three countries: the U.S., Canada, and New Zealand. You must be certified in each country you target. Audiences must be 18 or older.

What the gate opens up. Authorized telehealth advertisers can run efficacy compares, sales CTAs, delivery details, price notes, and consult copy. The full range of prescription-drug ads sits behind this gate. Categorical enforcement runs downstream. It sorts clean creative from bad, but only for authorized advertisers.

Compounded semaglutide and the manufacturer path. Meta's rules list "compounding" as a qualifying activity under Pharmaceutical Manufacturers. A pharmacy that compounds semaglutide can use the maker path. Two options: Meta's internal review, or LegitScript. Does Meta score compounded products the same as FDA-approved brands? That varies by product and by ad surface. Section 02 covers what we see.

SECTION 02 · Four scenarios

The four enforcement scenarios that hit this vertical

Four events hit GLP-1 telehealth accounts. Each has its own signal source and its own fix path. They stack in order of severity. Ad-level events come first. Account-level events follow. Multi-account events sit at the top.

Scenario 01

Ad rejected for misleading health claims

In the accounts we monitor, this is the most common rejection pattern. It fires on efficacy claims, before-and-after framing, or number claims ("Lose 30 lbs in 60 days"). Personal-attributes targeting ("Are you overweight?") also trips it. In our monitored cases, these patterns have mapped to misleading-claims or health-content enforcement signals; Ads Manager tends to surface only the broad group.Enforcement Signal Layer shows the exact code. Ads Manager shows only the broad group.

Ad-level · Most common

Scenario 02

Brand-drug conflation without pharmacy authority

Ad copy or landing page names an FDA-approved brand drug (Wegovy, Ozempic, Mounjaro, Zepbound) without pharmacy authority. In some monitored cases, licensed telehealth advertisers prescribing compounded versions have received additional enforcement after using brand-drug names. In our observed cases, brand-drug references can create an authority mismatch when the advertiser does not have the authorization Meta requires for that activity.

Ad-level · Authority mismatch

Scenario 03

Account restricted with spend-cap reduction (silent)

This is the quietest signal in the lane. In some accounts we monitor, changes in spending capacity have appeared before a visible rejection or restriction. In our model, this can be an early account-level signal rather than an isolated budget issue. It often traces back to past policy hits. See the full mechanics on /solutions/recovery Stage 04.

Account-level · Quiet throttle

Scenario 04

Multi-account suspension cascade

Our Asset Risk Propagation model tracks how enforcement on one account can expose connected business assets, identities, and payment relationships. In the accounts we monitor, multi-account impact can surface across connected assets before the full operational impact is visible in the advertiser's workflow.Asset Risk Propagation. The ban shows up in Ads Manager only after the signal has built up in the

Multi-account · Terminal

SECTION 03 · Compliant positioning

Language patterns associated with lower enforcement risk

Approved ad-pattern for GLP-1: process language with licensure attribution

Across the GLP-1 telehealth accounts we monitor, these patterns have been associated with lower enforcement risk. They are examples, not approval guarantees. Landing-page compliance still matters. Our Enforcement Signal Layer model surfaces the enforcement signals we track across the vertical.

"Online weight loss treatment"
"GLP-1 medication, prescribed by licensed clinicians"
"Telehealth weight loss program"
"Board-certified physician reviews your case"
"FDA-approved Wegovy® for chronic weight management" (only if the ad is actually for Wegovy and the advertiser holds pharmacy authority)
"Compounded semaglutide, not FDA-approved, prescribed off-label by licensed providers" (with the disclaimer explicit)
"Medical treatment provided by licensed providers"
Process language: "Quick consultation," "Personalized treatment plan," "Medication delivered to your door"

These are illustrations of compliant positioning, not a guarantee. Categorical enforcement means even compliant copy sometimes gets rejected. Use them as reference for the direction, not as a whitelist.

SECTION 04 · High-risk language

Language patterns associated with rejection

Auto-reject ad-pattern for GLP-1: instant guaranteed dollar-outcome language

Direct weight-loss outcome claims ("Lose 30 lbs in 60 days"): misleading-claims or prohibited-health-content policy family
Before-and-after imagery (any visible body-shape transformation): has shown a high rejection rate in our monitored cases
Personal-attributes targeting language ("Are you overweight?" / "Tired of being obese?"): personal-attributes policy
Brand-drug references without pharmacy authority: have been associated with rejection or additional review in our monitored cases
Quantified efficacy claims with specific percentages or pounds: have been associated with higher enforcement risk in our monitored cases, including where the underlying claim was factually supported
Conflation of compounded medications with brand-name approved drugs: has been associated with rejection in our monitored cases
Drug imagery (pills, syringes, vials): has been associated with elevated enforcement risk in our monitored cases

These patterns materially increase enforcement risk in our observations and should be reviewed before submission. The fix is creative-level, not appeal-level. Rephrasing after rejection tends not to clear the underlying signal. The pattern needs to be absent from the ad at submission.

SECTION 05 · Landing-page compliance

Landing-page elements associated with stronger compliance

GLP-1 landing-page compliance elements checklist

In our monitored cases, these elements have been associated with stronger landing-page compliance for telehealth weight-loss and GLP-1 advertisers. Landing-page content can affect the compliance assessment of an ad, so we treat the destination page as part of the review surface. In ComplyAi's Asset Risk Propagation model, landing-page compliance is part of the connected surface we monitor alongside the ad. Landing-page signals feed into Asset Risk Propagation across the connected asset graph.

Prescription-required language. "Prescription medication available with valid consultation," explicit on every page that mentions GLP-1.
Licensed-provider documentation. Provider credentials visible, state licensure visible.
FDA disclaimer for compounded products. "Not FDA-approved. Prescribed by licensed clinicians off-label."
Clinical / regulatory tone, not direct-response marketing tone. Use the language a telehealth practice would use, not the language a supplement DTC would use.
No before-and-after imagery on the landing page. The landing page is part of Meta's review surface, not separate from it.
No quantified outcome claims in headline or hero.

Compliance work that stops at the ad creative misses part of Meta's review surface. Asset Risk Propagation evaluates the ad and landing page as connected assets. In our monitored accounts, landing-page compliance gaps can coincide with broader account-level enforcement.

SECTION 06 · Vertical-specific recovery

Recovery path when this vertical's accounts hit enforcement

When a GLP-1 telehealth account hits enforcement, the recovery pattern is vertical-specific. The Ads Manager message is too broad to anchor an appeal. In our observation, three factors correlate with clearance: the exact violation code, the creative element that tripped it, and whether the product is compounded or FDA-approved.

The actual violation code drives the outcome.

Ads Manager surfaces a generic health-claim message. The specific code sits deeper in the Enforcement Signal Layer. Misleading claims, prohibited health content, and personal attributes are three different code families. In our observation, appeals that reference the specific code read differently to the review lane than appeals that reference the generic Ads Manager text.

The specific creative element matters.

Headline, image, and landing-page hero map to different code families. In our observation, appeals that identify the specific triggering element perform differently from appeals framed against the ad as a whole.

The relevant carve-outs are vertical-specific.

For GLP-1, three carve-outs recur: compounded-prescription proof, licensed-provider attestation, and FDA disclaimer language. Which one applies depends on the code and the product state.

If the account is restricted (not yet suspended), address at the restriction stage.

Across the accounts we monitor, most suspensions follow an earlier restriction signal in the weeks before terminal action. In our observation, restrictions serve as a leading indicator of suspension risk.

If a policy-code disablement has landed, the appeal is typically non-appealable.

A May 2026 Meta Pro Team response reviewed by ComplyAi indicated that, in the case reviewed, the policy-code disablement was not eligible for further appeal. That does not guarantee the same outcome for every account. At that point, business-identity reputation becomes the primary concern; adjacent ad accounts on the same identity carry cascade-exposure risk.

In our Q2 2026 Intelligence Graph, appeals that referenced the exact violation code showed a 30-35% overturn rate. Generic appeals performed materially worse in our observed cohort. For the full cascade mechanics, see /solutions/recovery. For the full appeal steps, see the Meta Ad Account Reinstatement guide.

Full step-by-step reinstatement playbook lives at Meta Ad Account Reinstatement.

SECTION 07 · Adjacent-vertical patterns

Cross-vertical spillover risk

Cross-vertical spillover timeline: CBD then supplements then GLP-1

GLP-1 telehealth does not sit alone. The Intelligence Graph tracks observed spillover patterns across adjacent regulated-health advertising lanes:

CBD waves preceded Supplement waves by several weeks. In our Q2 2026 Intelligence Graph analysis, CBD enforcement activity preceded observed Supplement activity by several weeks in the high-confidence cohort. Our monitored cycles show GLP-1 telehealth activity sometimes following the Supplement wave. The exact lag varies across cycles.
Compounded-drug enforcement has sometimes followed brand-drug policy shifts. When Meta tightens on Wegovy or Ozempic, we've seen compounded GLP-1 activity follow within weeks in our monitored cycles (subscriber observation, window not measured).
In our observed cycles, health-claim enforcement activity has appeared across adjacent lanes. In our observed cycles, a wave in one health-adjacent lane has sometimes appeared alongside activity in other health-adjacent lanes during the same cycle.

Cross-account pattern reading is the early warning. Single-account watching misses the wave. Subscribers here get the cross-account view: the wave that reaches your accounts is often visible on other accounts in the lane first. Reading that signal gives teams an opportunity to investigate and remediate before the same pattern reaches their accounts. That is why the Pillar 5 hub at /blog/scale-meta-ads-safely frames scaling as a signal-reading job, not a spend-management job. In this lane, ad-spend continuity is a signal problem, not a paperwork one.

Meta Ad Compliance for Weight Loss & GLP-1

Categorical enforcement mechanics, the four enforcement scenarios, and the recovery path

Why this vertical sits at Meta's highest enforcement tier

The authorization gate that stops most GLP-1 ads before enforcement even fires